KROS posts a wider Q1 loss as revenues fall due to the absence of license revenues. The company advances rinvatercept and ...

The Germany Anemia Treatment Market is set to reach USD 1.05 billion by 2034, growing at a CAGR of 6.84% from USD 581.344 million in 2025. This growth is driven by an aging population, increased ...

Stuart Orkin and Swee Lay Thein shared a Breakthrough Prize in Life Sciences for their research on genetic causes of sickle ...

Study in adults and children with aplastic anemia identifies parallel evolutionary pathways used by hematopoietic stem cells ...

Aboard Air Force One (AFP) | 15/05/2026 - 13:11:51 | Trump says Xi 'feels strongly' Iran can't have nuclear weapon ...

About 100,000 Americans have sickle cell disease (SCD), the most common inherited blood disorder in the US. Roughly 10% of patients reside in New York State, with the majority living in NYC, ...

A new study led by scientists atNorthwell Health’s Feinstein Institutes for Medical Researchhas revealed that defects in ...

Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of ...

Doctors at Artemis Hospitals have successfully treated India's first MYSM1-related bone marrow failure syndrome case using a ...

A genomic study of the largest pediatric and adult aplastic anemia cohort genetically profiled to date, finds that protective ...

Memo to mom and dad. While the goal of parents everywhere is to ensure their children survive into adulthood intact, many may be unwittingly putting their kids at risk. Speaking to The Post, a ...

Johnson & Johnson secured fast-track status for its autoimmune drug Imaavy, accelerating the regulatory timeline for what could become the first approved treatment for warm autoimmune hemolytic anemia ...